1340 Autologous Muscle Derived Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Multi-Center Experience

Peters, Kenneth M.; Kaufman, Melissa R.; Dmochowski, Roger R.; Carr, Lesley K.; Herschorn, Sender; Fischer, M; Sirls, Larry; Nagaraju, Pradeep; Biller, Daniel H; Chancellor, Michael B.

doi:10.1016/j.juro.2011.02.1161

Cited by 14 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…presented supportive data to show the safety of autologous MDSC injections in a large, multicentre trial of patients with SUI. 63 Although the study was underpowered to determine the exact efficacy of each treatment dose, the data suggest a general correlation between increasing stem cell dose and benefit to the recipient. However, these clinical studies failed to elucidate the mechanism of action of stem cells, partly because, in humans, we are unable to track the injected cells in vivo and it can be difficult to acquire human tissue for analysis.…”

Section: Stem Cell Therapy For Voiding Dysfunctionmentioning

confidence: 99%

Stem cell therapy for voiding and erectile dysfunction

et al. 2012

View full text Add to dashboard Cite

Voiding dysfunction comprises a variety of disorders, including stress urinary incontinence and overactive bladder, and affects millions of men and women worldwide. Erectile dysfunction (ED) also decreases quality of life for millions of men, as well as for their partners. Advanced age and diabetes are common comorbidities that can exacerbate and negatively impact upon the development of these disorders. Therapies that target the pathophysiology of these conditions to halt progression are not currently available. However, stem cell therapy could fill this therapeutic void. Stem cells can reduce inflammation, prevent fibrosis, promote angiogenesis, recruit endogenous progenitor cells, and differentiate to replace damaged cells. Adult multipotent stem cell therapy, in particular, has shown promise in case reports and preclinical animal studies. Stem cells have also enabled advances in urological tissue engineering by facilitating ex vivo construction of bladder wall and urethral tissue (using a patient's own cells) prior to transplantation. More recent studies have focused on bioactive factor secretion and homing of stem cells. In the future, clinicians are likely to utilize allogeneic stem cell sources, intravenous systemic delivery, and ex vivo cell enhancement to treat voiding dysfunction and ED.

show abstract

Section: Stem Cell Therapy For Voiding Dysfunctionmentioning

confidence: 99%

Stem cell therapy for voiding and erectile dysfunction

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Allogenic human umbilical cord blood stem cells have been studied by injecting these stem cells into the urethral submucosa of 39 women with SUI [49]. Recently, an ongoing study that utilized autologous MDSCs to treat SUI was also reported [50]. The effectiveness was similar to conventional bulking agents.…”

Section: Clinical Trials On Humansmentioning

confidence: 99%

Development of stem cell therapy for stress urinary incontinence

Bhatia²

2012

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

“…In addition to the clinical study reported in the Gräs and Lose article, they add only 1 article, which is actually an abstract from a multicenter experience. 1 The preliminary report details the dose escalation study designed to evaluate the safety and potential effectiveness of 4 different doses of autologous muscle derived cells originally obtained by biopsy of the lateral thigh muscle, followed by cell isolation and subsequent proliferation in culture. The cells were ultimately injected into the urinary sphincter area.…”

Section: Alternative Expedited and Safe Approaches Are In High Demandmentioning

confidence: 99%

Re: The Clinical Relevance of Cell-Based Therapy for the Treatment of Stress Urinary Incontinence

Wein¹

2012

Journal of Urology

View full text Add to dashboard Cite

pelvic floor muscle training was suggestive of benefit at three months but it is not known if this was sustained, and the treatment was associated with high levels of postoperative retention and dysuria. Greater symptomatic improvement was observed with surgical treatments, though the advantages need to be set against likely higher risks. No clear-cut conclusions could be drawn from trials comparing alternative agents, although dextranomer hyaluronic acid was associated with more local side effects and is no longer commercially available for this indication. There is insufficient evidence to show superiority of mid-urethral or bladder neck injection. The single trial of autologous fat provides a reminder that periurethral injections can occasionally cause serious side effects.Editorial Comment: This is an updated review of an analysis of periurethral injection therapy originally published in 2007 by the same group. Readers should be aware of the fact that Contigen® (glutaraldehyde cross-linked bovine collagen), previously available from Bard®, is no longer manufactured. I had our drug information people confirm this with Bard. Bard recommends another company that they say has a "similar product." The bottom line regarding this Cochrane Collaboration seems to be expressed under "implications for practice": "The lack of long-term followup and health economic data means that at present, injection therapy cannot be recommended as an alternative therapy for women fit for other surgical procedures. Reported outcomes are variable and at times poor, and the finding of a placebo response in a single trial means that comment concerning the usefulness of injection therapy as a first-line option is not evidencebased. For women with extensive co-morbidity precluding anesthesia, injection therapy may represent a useful option for relief of symptoms, at least for a 12-month period. The patient and healthcare provider should know that two or three injection sessions may be required and a satisfactory result is not guaranteed." Acta Obstet Gynecol Scand 2011; 90: 815-824. Stress urinary incontinence is a common disorder affecting the quality of life for millions of women worldwide. Effective surgical procedures involving synthetic permanent meshes exist, but significant short-and long-term complications occur. Cell-based therapy using autologous stem cells or progenitor cells presents an alternative approach, which aims at repairing the anatomical components of the urethral continence mechanism. In vitro expanded progenitor cells isolated from muscle biopsies have been most intensely investigated, and both preclinical trials and a few clinical trials have provided proof of concept for the idea. An initial enthusiasm caused by positive results from early clinical trials has been dampened by the recognition of scientific irregularities. At the same time, the safety issue for cell-based therapy has been highlighted by the appearance of new and comprehensive regulatory demands. The influence on the cost effectiveness, the clinical...

show abstract

1340 Autologous Muscle Derived Cell Therapy for the Treatment of Female Stress Urinary Incontinence: A Multi-Center Experience

Cited by 14 publications

References 0 publications

Stem cell therapy for voiding and erectile dysfunction

Stem cell therapy for voiding and erectile dysfunction

Development of stem cell therapy for stress urinary incontinence

Re: The Clinical Relevance of Cell-Based Therapy for the Treatment of Stress Urinary Incontinence

Contact Info

Product

Resources

About